Philogen

Philogen is a Swiss-Italian integrated biotechnology company founded in 1996, with the mission to develop innovative biopharmaceuticals for the treatment of angiogenesis-related disorders. Angiogenesis, i.e. the formation ... Read all

NEWS

Philogen S.p.A. announced that the European Commission (EC) has granted Orphan Drug Designation to L19TNF for the treatment of soft-tissue sarcoma.

Read all

PIPELINE

Philogen is a fully integrated company active in the discovery, GMP production and clinical development of immunomodulatory biopharmaceuticals. We have a leading position in the field of antibody-based therapeutics ... Read all

PARTNERS

Philochem is a fully owned daughter company of Philogen and represents the Discovery Unit of the Philogen group.

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all of the cookies, please refer to the cookie policy. By closing this banner, scrolling this page, clicking a link or continuing to browse otherwise, you agree to the use of cookies.

I Accept Cookie Policy